Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR).

P. Maslak,Tao Dao,Yvette Bernal,Suzanne Chanel,Rong Zhang,Mark G. Frattini,Todd L. Rosenblat,Joseph G. Jurcic,Raajit Rampal,Jae Hong Park,Dan Douer,Laura Katz,Andres A Gutierrez,Martin S. Tallman,David A. Scheinberg

Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR).

2016

P. Maslak
Tao Dao
Yvette Bernal
Suzanne Chanel
Rong Zhang
Mark G. Frattini
Todd L. Rosenblat
Joseph G. Jurcic
Raajit Rampal
Jae Hong Park
Dan Douer
Laura Katz
Andres A Gutierrez
Martin S. Tallman
David A. Scheinberg

7005Background: An NCI consensus study on prioritization of cancer antigens identified WT1 as the #1 ranked immunotherapy target. We previously reported on the safety, immunogenicity, and prolonged...

Keywords:

Myeloid leukemia
WT1 Analog Peptide Vaccine
Oncology
Pathology
Internal medicine
Medicine
Immunotherapy
Prioritization
Cancer
complete remission
Immunogenicity
Antigen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations